IO Biotech, Inc. (NASDAQ: IOBT) Stock Competitors & Peer Comparison
See IOBT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IOBT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IOBT | $0.01 | -27.59% | 885.7K | -0.05 | -$0.23 | N/A |
| VRTX | $558.88 | +3.50% | 141.7B | 29.37 | $19.03 | N/A |
| REGN | $927.89 | +13.33% | 95.5B | 20.32 | $45.63 | +0.40% |
| MRNA | $221.72 | -0.47% | 88.5B | -27.19 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $892.87 | -0.55% | 54.8B | 32.19 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.81 | +1.82% | 41.8B | -1.12 | -$8.82 | N/A |
| RVMD | $191.31 | +0.55% | 41B | -21.69 | -$8.82 | N/A |
| ONC | $370.33 | -0.33% | 39.6B | 65.20 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
IOBT vs VRTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, VRTX has a market cap of 141.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while VRTX trades at $558.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas VRTX's P/E ratio is 29.37. In terms of profitability, IOBT's ROE is -27.64%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IOBT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
IOBT vs REGN Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, REGN has a market cap of 95.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while REGN trades at $927.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas REGN's P/E ratio is 20.32. In terms of profitability, IOBT's ROE is -27.64%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IOBT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
IOBT vs MRNA Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, MRNA has a market cap of 88.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while MRNA trades at $221.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas MRNA's P/E ratio is -27.19. In terms of profitability, IOBT's ROE is -27.64%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, IOBT is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
IOBT vs VRNA Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IOBT's ROE is -27.64%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, IOBT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
IOBT vs ARGX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ARGX has a market cap of 54.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ARGX trades at $892.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ARGX's P/E ratio is 32.19. In terms of profitability, IOBT's ROE is -27.64%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, IOBT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
IOBT vs SGEN Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IOBT's ROE is -27.64%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IOBT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
IOBT vs RVMDW Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RVMDW trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, IOBT's ROE is -27.64%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, IOBT is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
IOBT vs RVMD Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RVMD trades at $191.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RVMD's P/E ratio is -21.69. In terms of profitability, IOBT's ROE is -27.64%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, IOBT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
IOBT vs ONC Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ONC has a market cap of 39.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ONC trades at $370.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ONC's P/E ratio is 65.20. In terms of profitability, IOBT's ROE is -27.64%, compared to ONC's ROE of +0.14%. Regarding short-term risk, IOBT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ONC's competition here
Genmab A/S (NASDAQ: GMAB)
IOBT vs GMAB Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, GMAB has a market cap of 34.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while GMAB trades at $57.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas GMAB's P/E ratio is 42.57. In terms of profitability, IOBT's ROE is -27.64%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IOBT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
IOBT vs ROIV Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ROIV has a market cap of 26.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ROIV trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ROIV's P/E ratio is -35.10. In terms of profitability, IOBT's ROE is -27.64%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, IOBT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
IOBT vs UTHR Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, UTHR has a market cap of 25.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while UTHR trades at $598.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas UTHR's P/E ratio is 21.42. In terms of profitability, IOBT's ROE is -27.64%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, IOBT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check UTHR's competition here
Insmed Incorporated (NASDAQ: INSM)
IOBT vs INSM Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, INSM has a market cap of 24.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while INSM trades at $112.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas INSM's P/E ratio is -27.40. In terms of profitability, IOBT's ROE is -27.64%, compared to INSM's ROE of -0.83%. Regarding short-term risk, IOBT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
IOBT vs INCY Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while INCY trades at $120.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas INCY's P/E ratio is 16.18. In terms of profitability, IOBT's ROE is -27.64%, compared to INCY's ROE of +0.07%. Regarding short-term risk, IOBT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
IOBT vs ALNY Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ALNY has a market cap of 22B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ALNY trades at $165.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ALNY's P/E ratio is 29.68. In terms of profitability, IOBT's ROE is -27.64%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, IOBT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
IOBT vs BNTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, BNTX has a market cap of 21.9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while BNTX trades at $88.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas BNTX's P/E ratio is -11.43. In terms of profitability, IOBT's ROE is -27.64%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, IOBT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
IOBT vs BGNE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IOBT's ROE is -27.64%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, IOBT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
IOBT vs DNA-WT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IOBT's ROE is -27.64%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, IOBT is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
IOBT vs EXEL Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, EXEL has a market cap of 17.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while EXEL trades at $69.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas EXEL's P/E ratio is 19.83. In terms of profitability, IOBT's ROE is -27.64%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, IOBT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
IOBT vs ASND Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ASND trades at $251.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ASND's P/E ratio is -103.74. In terms of profitability, IOBT's ROE is -27.64%, compared to ASND's ROE of +1.90%. Regarding short-term risk, IOBT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ASND's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
IOBT vs HALO Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, HALO has a market cap of 14.9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while HALO trades at $130.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas HALO's P/E ratio is 24.43. In terms of profitability, IOBT's ROE is -27.64%, compared to HALO's ROE of +1.81%. Regarding short-term risk, IOBT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check HALO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
IOBT vs NBIX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, NBIX has a market cap of 14.9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while NBIX trades at $146.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas NBIX's P/E ratio is 21.11. In terms of profitability, IOBT's ROE is -27.64%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, IOBT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check NBIX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
IOBT vs BBIO Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while BBIO trades at $74.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas BBIO's P/E ratio is -20.04. In terms of profitability, IOBT's ROE is -27.64%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, IOBT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
IOBT vs JAZZ Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, JAZZ has a market cap of 14B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while JAZZ trades at $215.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas JAZZ's P/E ratio is 8.05. In terms of profitability, IOBT's ROE is -27.64%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, IOBT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check JAZZ's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
IOBT vs SMMT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, SMMT has a market cap of 12.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while SMMT trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas SMMT's P/E ratio is -14.31. In terms of profitability, IOBT's ROE is -27.64%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, IOBT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
IOBT vs KRTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IOBT's ROE is -27.64%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IOBT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
IOBT vs TECH Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while TECH trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas TECH's P/E ratio is 37.46. In terms of profitability, IOBT's ROE is -27.64%, compared to TECH's ROE of +0.09%. Regarding short-term risk, IOBT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check TECH's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
IOBT vs BMRN Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while BMRN trades at $58.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas BMRN's P/E ratio is 28.14. In terms of profitability, IOBT's ROE is -27.64%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, IOBT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
IOBT vs RNAM Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IOBT's ROE is -27.64%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, IOBT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
IOBT vs KYMR Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, KYMR has a market cap of 10.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while KYMR trades at $126.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas KYMR's P/E ratio is -39.58. In terms of profitability, IOBT's ROE is -27.64%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, IOBT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check KYMR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
IOBT vs TWST Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, TWST has a market cap of 10.1B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while TWST trades at $152.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas TWST's P/E ratio is -68.83. In terms of profitability, IOBT's ROE is -27.64%, compared to TWST's ROE of -0.30%. Regarding short-term risk, IOBT is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
IOBT vs MDGL Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while MDGL trades at $430.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas MDGL's P/E ratio is -33.62. In terms of profitability, IOBT's ROE is -27.64%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, IOBT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check MDGL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
IOBT vs KRYS Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while KRYS trades at $332.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas KRYS's P/E ratio is 41.60. In terms of profitability, IOBT's ROE is -27.64%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IOBT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check KRYS's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
IOBT vs PCVX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, PCVX has a market cap of 9.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while PCVX trades at $62.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas PCVX's P/E ratio is -8.13. In terms of profitability, IOBT's ROE is -27.64%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, IOBT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check PCVX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
IOBT vs CAI Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CAI has a market cap of 9.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CAI trades at $34.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CAI's P/E ratio is 96.46. In terms of profitability, IOBT's ROE is -27.64%, compared to CAI's ROE of +0.19%. Regarding short-term risk, IOBT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CAI's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
IOBT vs RXDX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IOBT's ROE is -27.64%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IOBT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
IOBT vs PTGX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while PTGX trades at $144.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas PTGX's P/E ratio is 140.75. In terms of profitability, IOBT's ROE is -27.64%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, IOBT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check PTGX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
IOBT vs TGTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, TGTX has a market cap of 9.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while TGTX trades at $61.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas TGTX's P/E ratio is 22.17. In terms of profitability, IOBT's ROE is -27.64%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, IOBT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check TGTX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
IOBT vs NUVL Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas NUVL's P/E ratio is -21.79. In terms of profitability, IOBT's ROE is -27.64%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IOBT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check NUVL's competition here
10x Genomics, Inc. (NASDAQ: TXG)
IOBT vs TXG Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, TXG has a market cap of 9.1B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while TXG trades at $70.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas TXG's P/E ratio is -118.82. In terms of profitability, IOBT's ROE is -27.64%, compared to TXG's ROE of -0.09%. Regarding short-term risk, IOBT is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check TXG's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
IOBT vs CRNX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CRNX's P/E ratio is -16.86. In terms of profitability, IOBT's ROE is -27.64%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IOBT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CRNX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
IOBT vs SYRE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, SYRE has a market cap of 8.9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while SYRE trades at $96.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas SYRE's P/E ratio is -49.54. In terms of profitability, IOBT's ROE is -27.64%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, IOBT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check SYRE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
IOBT vs IBRX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while IBRX trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas IBRX's P/E ratio is -8.54. In terms of profitability, IOBT's ROE is -27.64%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, IOBT is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check IBRX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
IOBT vs CYTK Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CYTK has a market cap of 8.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CYTK trades at $62.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CYTK's P/E ratio is -8.72. In terms of profitability, IOBT's ROE is -27.64%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, IOBT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CYTK's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
IOBT vs IMGN Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IOBT's ROE is -27.64%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IOBT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check IMGN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
IOBT vs ARWR Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ARWR trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ARWR's P/E ratio is -26.61. In terms of profitability, IOBT's ROE is -27.64%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, IOBT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ARWR's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
IOBT vs APGE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas APGE's P/E ratio is -31.19. In terms of profitability, IOBT's ROE is -27.64%, compared to APGE's ROE of -0.30%. Regarding short-term risk, IOBT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
IOBT vs BPMC Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IOBT's ROE is -27.64%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, IOBT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
IOBT vs CERE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CERE's P/E ratio is -16.47. In terms of profitability, IOBT's ROE is -27.64%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IOBT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CERE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
IOBT vs PRAX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, PRAX has a market cap of 8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while PRAX trades at $285.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas PRAX's P/E ratio is -22.10. In terms of profitability, IOBT's ROE is -27.64%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, IOBT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check PRAX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
IOBT vs AXSM Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, AXSM has a market cap of 7.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while AXSM trades at $144.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas AXSM's P/E ratio is -37.77. In terms of profitability, IOBT's ROE is -27.64%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, IOBT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check AXSM's competition here
Abivax S.A. (NASDAQ: ABVX)
IOBT vs ABVX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ABVX has a market cap of 7.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ABVX trades at $86.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ABVX's P/E ratio is -14.19. In terms of profitability, IOBT's ROE is -27.64%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, IOBT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ABVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
IOBT vs MTSR Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IOBT's ROE is -27.64%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, IOBT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
IOBT vs IONS Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while IONS trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas IONS's P/E ratio is -13.31. In terms of profitability, IOBT's ROE is -27.64%, compared to IONS's ROE of -1.11%. Regarding short-term risk, IOBT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check IONS's competition here
Merus N.V. (NASDAQ: MRUS)
IOBT vs MRUS Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IOBT's ROE is -27.64%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, IOBT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
IOBT vs ACLX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IOBT's ROE is -27.64%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, IOBT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
IOBT vs RETA Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RETA's P/E ratio is -66.29. In terms of profitability, IOBT's ROE is -27.64%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IOBT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RETA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
IOBT vs LGND Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, LGND has a market cap of 6.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while LGND trades at $322.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas LGND's P/E ratio is 35.42. In terms of profitability, IOBT's ROE is -27.64%, compared to LGND's ROE of +0.05%. Regarding short-term risk, IOBT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check LGND's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
IOBT vs ORKA Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ORKA has a market cap of 6.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ORKA trades at $96.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ORKA's P/E ratio is -49.92. In terms of profitability, IOBT's ROE is -27.64%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, IOBT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ORKA's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
IOBT vs RYTM Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RYTM trades at $92.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RYTM's P/E ratio is -29.78. In terms of profitability, IOBT's ROE is -27.64%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, IOBT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RYTM's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
IOBT vs CNTA Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CNTA's P/E ratio is -22.63. In terms of profitability, IOBT's ROE is -27.64%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IOBT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
IOBT vs KOD Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while KOD trades at $99.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas KOD's P/E ratio is -23.78. In terms of profitability, IOBT's ROE is -27.64%, compared to KOD's ROE of -2.73%. Regarding short-term risk, IOBT is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
IOBT vs BLTE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while BLTE trades at $154.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas BLTE's P/E ratio is -82.96. In terms of profitability, IOBT's ROE is -27.64%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, IOBT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check BLTE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
IOBT vs TERN Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas TERN's P/E ratio is -51.41. In terms of profitability, IOBT's ROE is -27.64%, compared to TERN's ROE of -0.14%. Regarding short-term risk, IOBT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check TERN's competition here
Immunovant, Inc. (NASDAQ: IMVT)
IOBT vs IMVT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, IMVT has a market cap of 6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while IMVT trades at $29.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas IMVT's P/E ratio is -10.34. In terms of profitability, IOBT's ROE is -27.64%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, IOBT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check IMVT's competition here
Veradermics, Incorporated (NYSE: MANE)
IOBT vs MANE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while MANE trades at $139.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas MANE's P/E ratio is -44.48. In terms of profitability, IOBT's ROE is -27.64%, compared to MANE's ROE of -0.38%. Regarding short-term risk, IOBT is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check MANE's competition here
CG Oncology Inc. (NASDAQ: CGON)
IOBT vs CGON Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CGON trades at $64.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CGON's P/E ratio is -23.98. In terms of profitability, IOBT's ROE is -27.64%, compared to CGON's ROE of -0.25%. Regarding short-term risk, IOBT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CGON's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
IOBT vs CDTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IOBT's ROE is -27.64%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, IOBT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
IOBT vs ABCM Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IOBT's ROE is -27.64%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IOBT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
IOBT vs ISEE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IOBT's ROE is -27.64%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IOBT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ISEE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
IOBT vs MIRM Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while MIRM trades at $85.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas MIRM's P/E ratio is -5.83. In terms of profitability, IOBT's ROE is -27.64%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, IOBT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
IOBT vs COGT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while COGT trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas COGT's P/E ratio is -14.69. In terms of profitability, IOBT's ROE is -27.64%, compared to COGT's ROE of -0.73%. Regarding short-term risk, IOBT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check COGT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
IOBT vs SRRK Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while SRRK trades at $43.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas SRRK's P/E ratio is -12.72. In terms of profitability, IOBT's ROE is -27.64%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, IOBT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
IOBT vs APLS Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas APLS's P/E ratio is 38.35. In terms of profitability, IOBT's ROE is -27.64%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IOBT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
IOBT vs ERAS Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ERAS trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ERAS's P/E ratio is -15.41. In terms of profitability, IOBT's ROE is -27.64%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, IOBT is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ERAS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
IOBT vs PTCT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, PTCT has a market cap of 5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while PTCT trades at $59.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas PTCT's P/E ratio is -25.73. In terms of profitability, IOBT's ROE is -27.64%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, IOBT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
IOBT vs CRSP Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CRSP trades at $51.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CRSP's P/E ratio is -10.80. In terms of profitability, IOBT's ROE is -27.64%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, IOBT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
IOBT vs DFTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while DFTX trades at $36.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas DFTX's P/E ratio is N/A. In terms of profitability, IOBT's ROE is -27.64%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, IOBT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
IOBT vs TVTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while TVTX trades at $50.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas TVTX's P/E ratio is -111.98. In terms of profitability, IOBT's ROE is -27.64%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, IOBT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
IOBT vs DNTH Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while DNTH trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas DNTH's P/E ratio is -19.87. In terms of profitability, IOBT's ROE is -27.64%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, IOBT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check DNTH's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
IOBT vs FOLD Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IOBT's ROE is -27.64%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, IOBT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
IOBT vs AKRO Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IOBT's ROE is -27.64%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, IOBT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
IOBT vs ALPN Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IOBT's ROE is -27.64%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IOBT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ALPN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
IOBT vs ADPT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ADPT trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ADPT's P/E ratio is -64.93. In terms of profitability, IOBT's ROE is -27.64%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, IOBT is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ADPT's competition here
Opthea Limited (NASDAQ: OPT)
IOBT vs OPT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas OPT's P/E ratio is -1.52. In terms of profitability, IOBT's ROE is -27.64%, compared to OPT's ROE of +1.18%. Regarding short-term risk, IOBT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
IOBT vs PRTC Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas PRTC's P/E ratio is -3.78. In terms of profitability, IOBT's ROE is -27.64%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, IOBT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check PRTC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
IOBT vs EWTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while EWTX trades at $38.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas EWTX's P/E ratio is -21.03. In terms of profitability, IOBT's ROE is -27.64%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, IOBT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
IOBT vs MRTX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IOBT's ROE is -27.64%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IOBT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check MRTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
IOBT vs ARQT Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ARQT has a market cap of 4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ARQT trades at $32.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ARQT's P/E ratio is 152.62. In terms of profitability, IOBT's ROE is -27.64%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, IOBT is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ARQT's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
IOBT vs RLAY Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RLAY trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RLAY's P/E ratio is -11.68. In terms of profitability, IOBT's ROE is -27.64%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, IOBT is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RLAY's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
IOBT vs LEGN Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while LEGN trades at $21.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas LEGN's P/E ratio is -31.79. In terms of profitability, IOBT's ROE is -27.64%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, IOBT is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check LEGN's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
IOBT vs ABCL Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, ABCL has a market cap of 4B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while ABCL trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas ABCL's P/E ratio is -22.71. In terms of profitability, IOBT's ROE is -27.64%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, IOBT is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
IOBT vs CPRX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CPRX's P/E ratio is 17.49. In terms of profitability, IOBT's ROE is -27.64%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IOBT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CPRX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
IOBT vs IOVA Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while IOVA trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas IOVA's P/E ratio is -11.60. In terms of profitability, IOBT's ROE is -27.64%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, IOBT is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check IOVA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
IOBT vs TNGX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while TNGX trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas TNGX's P/E ratio is -27.37. In terms of profitability, IOBT's ROE is -27.64%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, IOBT is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check TNGX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
IOBT vs RYZB Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IOBT's ROE is -27.64%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IOBT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
IOBT vs CBAY Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IOBT's ROE is -27.64%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IOBT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check CBAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
IOBT vs XENE Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, XENE has a market cap of 3.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while XENE trades at $37.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas XENE's P/E ratio is -7.96. In terms of profitability, IOBT's ROE is -27.64%, compared to XENE's ROE of -0.44%. Regarding short-term risk, IOBT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
IOBT vs AMLX Comparison November 2026
IO Biotech, Inc. (NASDAQ: IOBT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOBT stands at 885.7K. In comparison, AMLX has a market cap of 3.6B. Regarding current trading prices, IOBT is priced at $0.01 on the NASDAQ, while AMLX trades at $28.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOBT currently has a P/E ratio of -0.05, whereas AMLX's P/E ratio is -19.24. In terms of profitability, IOBT's ROE is -27.64%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, IOBT is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for IOBT.Check AMLX's competition here